EN
SINOVAC Expands Strategic Partnership with Bio Farma, Bolstering Indonesia's Vaccine Supply
July 28, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a strengthened alliance with Indonesian state-owned biopharmaceutical company PT Bio Farma, marking another milestone in the two companies' joint efforts to serve Indonesia's domestic vaccine market as well as international market.
The partnership agreement was signed on July 27, during the Indonesia-China Healthcare and Biotech Investment Forum held in Chengdu, the capital city of Sichuan Province in southwest China. It was witnessed by Indonesian government officials that included Budi Gunadi Sadikin, Indonesian Minister of Health; Djauhari Oratmangun, Indonesian Ambassador to China; and Arsjad Rasjid, Chairman of the Indonesian Chamber of Commerce and Industry.
Bio Farma, Indonesia's single and largest state-owned biopharmaceutical company, is an integral strategic partner for SINOVAC. The two companies partnered to successfully arm Indonesia with over 280 million doses of the inactivated COVID-19 vaccine, CoronaVac®, employing an efficient dual-pronged approach that enabled local filling of SINOVAC's finished product. CoronaVac® was the first COVID-19 vaccine available in Indonesia, a critical step in bringing the pandemic under control and protecting local populations.
SINOVAC remains committed to growth within the Indonesian market. Several of its products are available in addition to CoronaVac®, including the inactivated hepatitis A vaccine Healive® and the inactivated EV71 vaccine Inlive®. SINOVAC also has plans to introduce future products, including its varicella, influenza, and pneumococcal polysaccharide vaccines, to meet the region’s healthcare needs and further enhance local and national public health efforts.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.